Pgiam/iStock via Getty Images Zymeworks ( NASDAQ: ZYME ) shares fell in the morning hours Friday after Wells Fargo downgraded the company, arguing that its stock already reflects a potential FDA nod for its cancer therapy zanidatamab developed with Jazz Pharma ( JAZZ ) and BeiGene ( BGNE ). The bispecific.
Back to Health Page
